Abstract
The selective accumulation and activation of leukocytes in inflamed tissues contributes to the pathogenesis of inflammatory and autoimmune diseases such as infection, rheumatoid arthritis, allergic asthma, atopic dermatitis, and multiple sclerosis. A substantial body of reports suggests that chemokines and their receptors, which belong to a family of seven transmembrane G-protein coupled receptors (GPCR), may be involved in the selective accumulation and activation of leukocytes in inflamed tissues, and in the pathogenesis of inflammatory and autoimmune diseases. One such receptor is CCR1 which is a receptor for CC chemokines, such as CCL5 (RANTES) and CCL3 (MIP-1α). The involvement of CCR1 in immunological diseases now is documented in several preclinical studies with CCR1 deficient mice, anti-CCR1 antibodies and CCR1 antagonists, suggesting that CCR1 may be an attractive therapeutic target for a variety of diseases. Publications and patents describing CCR1 antagonists and their pharmacological effects have recently been disclosed. This review highlights the biology and pathophysiology of CCR1, and some of its currently reported antagonists. Additionally, our approach to CCR1 drug discovery is summarized.
Keywords: chemokine, chemokine receptor, ccr1, ccr1 antagonist
Current Pharmaceutical Design
Title: CCR1 Chemokine Receptor Antagonist
Volume: 9 Issue: 15
Author(s): Toshihiko Saeki and Akira Naya
Affiliation:
Keywords: chemokine, chemokine receptor, ccr1, ccr1 antagonist
Abstract: The selective accumulation and activation of leukocytes in inflamed tissues contributes to the pathogenesis of inflammatory and autoimmune diseases such as infection, rheumatoid arthritis, allergic asthma, atopic dermatitis, and multiple sclerosis. A substantial body of reports suggests that chemokines and their receptors, which belong to a family of seven transmembrane G-protein coupled receptors (GPCR), may be involved in the selective accumulation and activation of leukocytes in inflamed tissues, and in the pathogenesis of inflammatory and autoimmune diseases. One such receptor is CCR1 which is a receptor for CC chemokines, such as CCL5 (RANTES) and CCL3 (MIP-1α). The involvement of CCR1 in immunological diseases now is documented in several preclinical studies with CCR1 deficient mice, anti-CCR1 antibodies and CCR1 antagonists, suggesting that CCR1 may be an attractive therapeutic target for a variety of diseases. Publications and patents describing CCR1 antagonists and their pharmacological effects have recently been disclosed. This review highlights the biology and pathophysiology of CCR1, and some of its currently reported antagonists. Additionally, our approach to CCR1 drug discovery is summarized.
Export Options
About this article
Cite this article as:
Saeki Toshihiko and Naya Akira, CCR1 Chemokine Receptor Antagonist, Current Pharmaceutical Design 2003; 9 (15) . https://dx.doi.org/10.2174/1381612033454937
DOI https://dx.doi.org/10.2174/1381612033454937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Targeting Leukotrienes for the Treatment of COPD?
Inflammation & Allergy - Drug Targets (Discontinued) Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Current Drug Targets The Immune-Endocrine-Metabolic Unit During Human Tuberculosis
Current Immunology Reviews (Discontinued) Herbal Nanoformulations for Asthma Treatment
Current Pharmaceutical Design Towards Improved Therapeutic CORMs: Understanding the Reactivity of CORM-3 with Proteins
Current Medicinal Chemistry Microporation Techniques for Enhanced Delivery of Therapeutic Agents
Recent Patents on Drug Delivery & Formulation Editorial (Hot Topic:Modulation of Cholinergic System Activity in Neuronal and Non-Neuronal Tissues: Therapeutic Implications)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Extraction of Triacylglycerols and Fatty Acids Using Supercritical Fluids - Review
Current Analytical Chemistry High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Extracellular Vesicles Derived from <i>Plasmodium</i>-infected Hosts as Stimuli of “Trained” Innate Immunity
Current Medicinal Chemistry Synovial Chondromatosis of the Shoulder in Rheumatoid Arthritis: A Case Report and Brief Review of the Literature
Current Rheumatology Reviews Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus
Current Diabetes Reviews